Cite
HARVARD Citation
Peters, S. et al. (n.d.). 57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results. Immuno-oncology technology. p. . [Online].